Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Duopharma Biotech Bhd's Enterprise Value is RM1,394.7 Mil.
Duopharma Biotech Bhd's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was RM67.7 Mil. Therefore, Duopharma Biotech Bhd's EV-to-FCF for today is 20.59.
The historical rank and industry rank for Duopharma Biotech Bhd's EV-to-FCF or its related term are showing as below:
XKLS:7148'
s EV-to-FCF Range Over the Past 10 Years
Min: -2465.88 Med: -16.62 Max: 467.63
Current: 20.73
During the past 13 years, the highest EV-to-FCF of Duopharma Biotech Bhd was 467.63. The lowest was -2465.88. And the median was -16.62.
XKLS:7148's EV-to-FCF is ranked better than 50.71% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs XKLS:7148: 20.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Duopharma Biotech Bhd (XKLS:7148) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Duopharma Biotech Bhd's PE Ratio (TTM) for today is calculated as:
Duopharma Biotech Bhd's share price for today is RM1.22.
Duopharma Biotech Bhd's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's EV-to-FCF falls into.
Duopharma Biotech Bhd's current Enterprise Value is RM1,394.7 Mil.
Duopharma Biotech Bhd's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM67.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a EV-to-FCF of 20.59 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Duopharma Biotech Bhd and its competitors. According to the industry distribution chart, Duopharma Biotech Bhd ranks #277 out of 562 companies in the Drug Manufacturers industry, placing it in the top 49.3%.
Is Duopharma Biotech Bhd's EV-to-FCF too high?
Duopharma Biotech Bhd's current EV-to-FCF is 20.59. The Drug Manufacturers industry median EV-to-FCF is 21.06. Duopharma Biotech Bhd's value of 20.59 is 2.2% below this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #277 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #277 out of 562 companies for EV-to-FCF. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median EV-to-FCF is 21.06. Duopharma Biotech Bhd's value of 20.59 is 2.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current EV-to-FCF of 20.59 is 2.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current EV-to-FCF is 20.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.22 — trading 20.3% below its estimated fair value. The current EV-to-FCF is 20.59 and 2.2% below the Drug Manufacturers industry median of 21.06. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current EV-to-FCF is 20.59 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.22 is trading 20.3% below its estimated GF Value™ of RM1.53.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
EV-to-FCF: 20.59
GF Value™: RM1.53 vs. price of RM1.22 (20.3% below fair value)
Industry Position: 2.2% below the Drug Manufacturers median (#277 of 562)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score
Get the complete analysis for XKLS:7148
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
